Press Release: Sanofi Q2 - strong performance with 10% sales growth; 2024 guidance upgraded
Sanofi Q2: strong performance with 10% sales growth; 2024 guidance upgraded Paris, July 25, 2024 Q2 sales growth of 10.2% at CER and business EPS(1) of €1.73 Dupixent sales up 29.2% to €3,303 million; target of ~€13 billion in 2024 unchanged Pharma …